Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L).

The presence of TP53 mutations has been shown to reduce the efficacy of ALK-TKI, and an analysis of the ALTA-1L trial showed a trend toward shorter PFS in patients with TP53 mutations who received either brigatinib or crizotinib. 10 An analysis of the CROWN trial also showed a similar trend for lorlatinib 11 , 12 ; however, no statistically significant difference was shown in this analysis and the significance of such compound mutations in ALK-TKI therapy is not fully understood.

also in 53,322 other papers